



Antibodies

11-380-C100

Monoclonal Antibody to CD11a Purified Antibody (0.1 mg)

Clone:	MEM-83
Isotype:	Mouse IgG1
Specificity:	The antibody MEM-83 reacts with CD11a (alpha subunit of human LFA-1), a 170-180 kDa type I transmembrane glycoprotein expressed on B and T lymphocytes, monocytes, macrophages, neutrophils, basophils and eosinophils. HLDA IV; WS Code N 211
Regulatory Status:	RUO
Immunogen:	Human peripheral blood lymphocytes
Species Reactivity:	Human
Application:	Functional Application The antibody MEM-83 directly induces the binding of T cells to purified ICAM-1. Using an in vitro-translated CD11a cDNA deletion series, the MEM-83 activation epitope was mapped to the "I" domain of the LFA-1 alpha subunit. The studies have therefore identified a novel LFA-1 activation epitope mapping to the I domain of LFA-1, which could play a role in the regulation of LFA-1 binding to ICAM-1. Flow Cytometry Recommended dilution: 1 µg/ml Immunoprecipitation
Purity:	> 95% (by SDS-PAGE)
Purification:	Purified by protein-A affinity chromatography
Concentration:	1 mg/ml
Storage Buffer:	Phosphate buffered saline (PBS) with 15 mM sodium azide, approx. pH 7.4
Storage / Stability:	Store at 2-8°C. Do not freeze. Do not use after expiration date stamped on vial label.
Expiration:	See vial label
Lot Number:	See vial label
Background:	CD11a (LFA-1 alpha) together with CD18 constitute leukocyte function-associated antigen 1 (LFA-1), the alphaLbeta2 integrin. CD11a is implicated in activation of LFA-1 complex. LFA-1 is expressed on the plasma membrane of leukocytes in a low-affinity conformation. Cell stimulation by chemokines or other signals leads to induction the high-affinity conformation, which supports tight binding of LFA-1 to its ligands, the intercellular adhesion molecules ICAM-1, -2, -3. LFA-1 is thus involved in interaction of various immune cells and in their tissue-specific settlement, but participates also in control of cell differentiation and proliferation and of T-cell effector functions. Blocking of LFA-1 function by specific antibodies or small molecules has become an important therapeutic approach in treatment of multiple inflammatory diseases. For example, humanized anti-LFA-1 antibody Efalizumab (Raptiva) is being used to interfere with T cell migration to sites of inflammation; binding of cholesterol-lowering drug simvastatin to CD11a allosteric site leads to immunomodulation and increase in lymphocytic cholinergic activity.

For laboratory research only, not for drug, diagnostic or other use.



Antibodies

References:

- *Sarantos MR, Raychaudhuri S, Lum AF, Staunton DE, Simon SI: Leukocyte function-associated antigen 1-mediated adhesion stability is dynamically regulated through affinity and valency during bond formation with intercellular adhesion molecule-1. *J Biol Chem.* 2005 Aug 5;280(31):28290-8.
- *Giblin PA, Lemieux RM: LFA-1 as a key regulator of immune function: approaches toward the development of LFA-1-based therapeutics. *Curr Pharm Des.* 2006;12(22):2771-95.
- *Kellersch B, Kolanus W: Membrane-proximal signaling events in beta-2 integrin activation. *Results Probl Cell Differ.* 2006;43:245-57.
- *Fujii T, Takada-Takatori Y, Kawashima K: Roles played by lymphocyte function-associated antigen-1 in the regulation of lymphocytic cholinergic activity. *Life Sci.* 2007 May 30;80(24-25):2320-4.
- *Leukocyte Typing IV., Knapp W. et al. (Eds.), Oxford University Press (1989).
- *Landis RC, Bennett RI, Hogg N: A novel LFA-1 activation epitope maps to the I domain. *J Cell Biol.* 1993 Mar;120(6):1519-27.
- *Landis RC, McDowall A, Holness CL, Littler AJ, Simmons DL, Hogg N: Involvement of the "I" domain of LFA-1 in selective binding to ligands ICAM-1 and ICAM-3. *J Cell Biol.* 1994 Jul;126(2):529-37.

Unless indicated otherwise, all products are For Research Use Only and not for diagnostic or therapeutic use. Not for resale or transfer either as a stand-alone product or as a component of another product without written consent of EXBIO. EXBIO will not be held responsible for patent infringement or other violations that may occur with the use of our products. All orders are accepted subject to EXBIO's term and conditions which are available at www.exbio.cz.

For laboratory research only, not for drug, diagnostic or other use.

EXBIO Praha | Nad Safinou II 341 | 252 50 Vestec u Prahy | Czech Republic
Tel: +420 261 090 666 | Fax: +420 261 090 660 | orders@exbio.cz | www.exbio.cz